by GlobeNewsWire | Sep 8, 2016 | Globe Newswire
EXTON, Pa., Sept. 08, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today reported the receipt of $18.1 million of gross proceeds from the sale of convertible promissory notes and warrants in its previously announced private placement financing....
by GlobeNewsWire | Aug 8, 2016 | Globe Newswire
EXTON, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) (Fibrocell) today announced that it intends to offer and sell shares of its common stock and related warrants to purchase shares of its common stock in an underwritten public...
by GlobeNewsWire | Aug 4, 2016 | Globe Newswire
EXTON, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the second quarter ended June 30, 2016 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m....
by GlobeNewsWire | Jul 27, 2016 | Globe Newswire
EXTON, Pa., July 27, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that the first two adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)....
by GlobeNewsWire | Jun 29, 2016 | Globe Newswire
EXTON, Pa., June 29, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today announced significant cost savings are expected from the wind-down of its azficel-T operations and that the Company is focusing its efforts and resources on its gene therapy...